Bionano Genomics, Inc.
Bionano Genomics, Inc.
Your view on BNGO
Overview
What the company does, where it operates, and who runs it.
About Bionano Genomics, Inc.
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Robert Erik Holmlin
- Headquarters
- 9540 Towne Centre Drive, San Diego, CA, US
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Robert Erik Holmlin
- Headquarters
- 9540 Towne Centre Drive, San Diego, CA, US
Bionano Genomics, Inc. provides genome analysis software solutions.
It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight.
The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics.
In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes.
The company was founded in 2003 and is headquartered in San Diego, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Bionano Genomics, Inc., and the rating behind it. BNGO last traded at $1.22; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Bionano Genomics, Inc.. Starting points for Bionano Genomics, Inc.: EPS -$2.79, beta 1.65 — an Medical - Instruments & Supplies name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Bionano Genomics, Inc.. Bionano Genomics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Bionano Genomics, Inc.. Trailing twelve-month EPS for Bionano Genomics, Inc. stands at -$2.79. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Bionano Genomics, Inc.. Bionano Genomics, Inc. has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Bionano Genomics, Inc. valued side by side against its closest peers. Bionano Genomics, Inc. is measured against Medical - Instruments & Supplies peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Bionano Genomics, Inc., and how their positions are changing. At a $14.0M market value, institutional positions materially move Bionano Genomics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Bionano Genomics, Inc. executives and directors. Shares of Bionano Genomics, Inc. have traded between $1.45 and $22.80 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Bionano Genomics, Inc.. Bionano Genomics, Inc. is a $14.0M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Bionano Genomics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Bionano Genomics, Inc.. Coverage tracks Bionano Genomics, Inc. within Medical - Instruments & Supplies (Healthcare). Press releases and market coverage, newest first.